Table 3.

Case series and reports of gynecologic melanoma treated with immune checkpoint inhibitors in details, based on Table 3 in Wohlmuth et al.

Author (Year)	Pt. No	Origin	1 Stage at Treatment Initiation	Primary Systemic Therapy	Treatment	iBOR	2 PFS	irAEs	3 OS	Status
Wohlmuth (2020) [26]	1	Vulva	III C, unresectable	None	Pembrolizumab	iCPD	2	None	18	Alive with disease
	2	Vulva	IV (lung)	None	Ipilimumab + nivolumab	iSD	18	Uveitis G1,peripheral sensory neuropathy G3	18	Alive with disesase
	3	Vulva	IV (liver)	None	Ipilimumab + nivolumab	iCPD	1	None	1	Died of disease
	4	Vulva	IV (liver)	None	Nivolumab	iPR	15	Hepatitis G1	15	Alive with disease
	5	Vagina	Distant (brain)	Nivolumab, adjuvant	Pembrolizumab	iSD	4	None	16	Died of disease
	6	Vulva	IV (lung)	None	Ipilimumab	iCR	56	None	56	Alive with NED
	7	Vulva	IV (lung, liver)	Interferon, adjuvant	1. Ipilimumab 2. Pembrolizumab	iCPD iSD	3 4	Maculopapular exanthema G1, Hepatitis G1 None	17	Died of disease
	8	Vulva	IV (liver)	None	1. Ipilimumab 2. Pembrolizumab	iCPD iPR	3 9	Maculopapular exanthema G1 None	50	Alive with disease
	9	Vulva	IV (lung, brain)	Carboplatin/paclitaxel	Ipilimumab	iCPD	3	None	6	Died of disease
	10	Vulva	IV (lung)	Dacarbazine	1. Ipilimumab 2. Pembrolizumab	iCPD iCR	3 77	None Hyperthyroidism G2, DM G3,Erythema nodosum G1	87	Alive with NED
	11	Vulva	IV (lung, bone)	None	Ipilimumab	iCPD	1	None	1	Died of disease
	12	Vulva	IV (lung, abdomen)	Carboplatin/paclitaxel	1. Ipilimumab 2. Pembrolizumab	iCPD iCPD	3 3	None None	16	Died of disease
	13	Vulva	IV (lung, abdomen, soft tissue)	Carboplatin/paclitaxel	Ipilimumab	iSD	2	None	13	Died of disease
Indini (2019) [29]	1	Vulva	IV (lung)	CVD	Ipilimumab	iCPD	4	None	7	Died of disease
	2	Vulva	IV (lung, bone)	None	Pembrolizumab	iPR	10	Arthralgia G2, hypothyroidism G2	10	Alive with disease
	3	Vagina	Distant (liver)	None	Pembrolizumab	iCPD	2	None	4	Alive with disease
	4	Vagina	Distant (n.s.)	None	Nivolumab	iSD	4	Cutaneous rash G1	4	Alive with disease
	5	Vagina	Distant (liver, pancreas, soft tissues, bone)	None	Ipilimumab	iCPD	3	None	7	Died of disease
	6	Vagina	Distant (lung)	Dacarbazine	Ipilimumab	iCPD	3	None	18	Died of disease
	7	Cervix	Distant (lung, liver)	None	Ipilimumab	iCPD	2	None	2	Died of disease
4 Quéreux (2017) [30]	1	Vulva or Vagina	5: Distant (mucosa and/or lymph nodes) 1: Distant (liver)	2: None 3: Chemotherapy 1: Nivolumab	Ipilimumab	4: iCPD		1: Asthenia G1 1: Colitis G1 1: Rheumatoid arthritis G1 1: Colitis G3	n.s.	The survival rate at 1 year: 33%
	2
	3
	4
	5					1: iSD	11		11
	6					1: iPR	31		31
	7	Vulva or Vagina	6: Distant (mucosa and/or lymph nodes) 2: None	4: None 1: Dacarbazine 1: BRAF and MEK inhibitors 2: Ipilimumab	Nivolumab	4: iPR 4: iCPD	n.s.	3: Asthenia G1 2: Maculopapular rush G1 2: Rheumatoid arthritis G2 1: Colitis G2	n.s	The survival rate at 1 year: 86%
	8
	9
	10
	11
	12
	13
	14
	15	Vagina	Distant (mucosa, lymph nodes, lung)	None	Ipilimumab + Nivolumab	iPR	5	Asthenia G1, Hypothyroidism G2	12	Alive with disease
4 Del Prete (2016) [31]	1	Vulva or Vagina	7: n.s. (surgery for total excision) 1: n.s. (unresectable)	1: pegylated interferon			n.s.	n.s.	n.s.
	2				3: Ipilimumab	1: iPR, 2: iPD				n.s.
	3				1: Pembrolizumab	iSD				Alive with disease
	4				1: Interferon pegintron	iSD				Alive with NED
	5				3: Imatinib	2: iPR, 1: iSD				n.s.
	6				1: Nilotinib	iCPD				n.s.
	7				5: Chemotherapy	1: iSD, 4: iCPD				n.s.
	8
Schiavone (2016) [32]	1	Vagina	localized, Ballantyne I	None	Ipilimumab	iSD	38	Maculopapular rush G3, Diarrhea G1	38	Alive with NED
	2	Vagina	localized, Ballantyne I	None	Ipilimumab	iCPD	2	None	16	Died of disease
	3	Vagina	localized, Ballantyne I	None	Ipilimumab	iCR	20	None	20	Alive with NED
	4	Cervix	localized, Ballantyne I	None	Ipilimumab Pembrolizumab	iCPD iSD	9 n.s.	Diarrhea G3 n.s.	19 n.s.	Alive with disease
Anko (2020) [33]	1	Vagina	Distant (liver, lung, bone)	None	Nivolumab	iPR/iCR	17	Thyroiditis, n.s	17	Alive
	2	Cervix	II C (None)	None	(recurrence)Nivolumab	iCR	33	None	33	Alive with disease
Cocorocchio (2020) [34]	1	Vulva	IV (lung, lymph nodes) IV (brain, adrenal gland, lung, subcutaneous) IV (breast, lung, stomach)	None	Ipilimumab + Nivolumab Nivolumab + RT(brain) Avapritinib	iSD iCPD iPR	10 4 11	Hyperglycemia G4 Hemiparesis, n.s. Vasculitis G2, uveitis G2	40	Died of disease
Komatsu-Fujii (2019) [35]	1	Vagina	Distant (lung)	None	Nivolumab Pembrolizumab Ipilimumab	iCPD iCPD iCPD	n.s n.s. n.s.	n.s. n.s. n.s.	n.s.	Alive with disease
Yamashita (2019) [36]	1	Vulva	1,2. IV (liver, lymph nodes) 3,4. IV (liver, lymph nodes, lung, gall bladder, renal duct)	None	Nivolumab Ipilimumab + RT (liver) Dacarbazine Pembrolizumab + imatinib	iCPD iCPD iCPD iPR	n.s. n.s. n.s.	Maculopapular rush G2	n.s.	Alive with disease
Norwood (2019) [37]	1	Vagina	Regional	None	(recurrence) Ipilimumab + Nivolumab	iSD	n.s.	Maculopapular rush G3, Colitis G2, Hyponatremia G2, Headache G2	n.s.	Alive with disease
Kim (2018) [38]	1	Cervix	Distant (bone, spine, lung, lymph nodes)	None	(adjuvant therapy) Pembrolizumab	iCPD	0	Maculopapular rush, n.s.	9	Died of disease
Daix (2018) [39]	1	Vagina	Regional, unresectable	None	Nivolumab	iCR	8	Pruritus G1	8	Alive with NED
Nai (2018) [40]	1	Cervix	Distant (liver, kidney)	None	Ipilimumab + Nivolumab	iCPD	0	None	12	Died of disease
Inoue (2018) [41]	1	Vagina	Distant (brain)	None	Nivolumab	iCPD	2	Hepatitis G3	n.s.	Alive with disease

¹ Stage: AJCC staging classification for vulvar melanoma, and local/regional/distantfor vaginal or cervical melanomas; ² PFS: from treatment initiation to date of progression or death; ³ OS: from treatment initiation to date of last follow-up or death; ⁴ No details of patients order in the treatment (ipilimumab, nivolumab, etc.). The leftmost number before colon indicates the number of patients in each group.Abbreviations: CVD indicates cisplatin-vinblastin-dacarbazine; Cervix, melanoma of uterine cervix; DM, diabetes mellitis; G, grade; iCPD, comfirmed progressive disease; irAEs, immune-related adverse events; NED, no evidence of disease; n.s., not specified; RT: radiotherapy.